Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation study of BNT314 monotherapy in advanced solid tumors
jRCT2031240313Phase 1Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of GEN1059 in Nonhematologic neoplasms, sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 2 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
GEN1059
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240313.